{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:53:26Z","timestamp":1781859206500,"version":"3.54.5"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1008434","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000}}],"reference-count":100,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009053","name":"The Wellcome Trust DBT India Alliance","doi-asserted-by":"publisher","award":["Senior Fellowship IA\/S\/14\/1\/501307"],"award-info":[{"award-number":["Senior Fellowship IA\/S\/14\/1\/501307"]}],"id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>Passive immunization with broadly neutralizing antibodies (bNAbs) of HIV-1 appears a promising strategy for eliciting long-term HIV-1 remission. When administered concomitantly with the cessation of antiretroviral therapy (ART) to patients with established viremic control, bNAb therapy is expected to prolong remission. Surprisingly, in clinical trials on chronic HIV-1 patients, the bNAb VRC01 failed to prolong remission substantially. Identifying the cause of this failure is important for improving VRC01-based therapies and unraveling potential vulnerabilities of other bNAbs. In the trials, viremia resurged rapidly in most patients despite suppressive VRC01 concentrations in circulation, suggesting that VRC01 resistance was the likely cause of failure. ART swiftly halts viral replication, precluding the development of resistance during ART. If resistance were to emerge post ART, virological breakthrough would have taken longer than without VRC01 therapy. We hypothesized therefore that VRC01-resistant strains must have been formed before ART initiation, survived ART in latently infected cells, and been activated during VRC01 therapy, causing treatment failure. Current assays preclude testing this hypothesis experimentally. We developed a mathematical model based on the hypothesis and challenged it with available clinical data. The model integrated within-host HIV-1 evolution, stochastic latency reactivation, and viral dynamics with multiple-dose VRC01 pharmacokinetics. The model predicted that single but not higher VRC01-resistant mutants would pre-exist in the latent reservoir. We constructed a virtual patient population that parsimoniously recapitulated inter-patient variations. Model predictions with this population quantitatively captured data of VRC01 failure from clinical trials, presenting strong evidence supporting the hypothesis. We attributed VRC01 failure to single-mutant VRC01-resistant proviruses in the latent reservoir triggering viral recrudescence, particularly when VRC01 was at trough levels. Pre-existing resistant proviruses in the latent reservoir may similarly compromise other bNAbs. Our study provides a framework for designing bNAb-based therapeutic protocols that would avert such failure and maximize HIV-1 remission.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1008434","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T14:13:44Z","timestamp":1606745624000},"page":"e1008434","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection"],"prefix":"10.1371","volume":"16","author":[{"given":"Ananya","family":"Saha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-9828","authenticated-orcid":true,"given":"Narendra M.","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"pcbi.1008434.ref001","first-page":"a007161","article-title":"HIV-1 Antiretroviral drug therapy.","volume":"2","author":"EJ Arts","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"pcbi.1008434.ref002","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/44755","article-title":"AIDS: Re-emergence of HIV after stopping therapy","volume":"401","author":"TW Chun","year":"1999","journal-title":"Nature"},{"key":"pcbi.1008434.ref003","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/ni.3152","article-title":"HIV reservoirs as obstacles and opportunities for an HIV cure","volume":"16","author":"TW Chun","year":"2015","journal-title":"Nat Immunol"},{"key":"pcbi.1008434.ref004","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1073\/pnas.95.15.8869","article-title":"Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection","volume":"95","author":"TW Chun","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pcbi.1008434.ref005","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1084\/jem.20170193","article-title":"Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics","volume":"214","author":"NN Hosmane","year":"2017","journal-title":"J Exp Med"},{"key":"pcbi.1008434.ref006","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1038\/s41467-018-06843-5","article-title":"A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation","volume":"9","author":"DB Reeves","year":"2018","journal-title":"Nat Commun"},{"key":"pcbi.1008434.ref007","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/8394","article-title":"Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy","volume":"5","author":"D Finzi","year":"1999","journal-title":"Nat Med"},{"key":"pcbi.1008434.ref008","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2005.06.006","article-title":"Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity","volume":"122","author":"LS Weinberger","year":"2005","journal-title":"Cell"},{"key":"pcbi.1008434.ref009","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"Y-C Ho","year":"2013","journal-title":"Cell"},{"key":"pcbi.1008434.ref010","doi-asserted-by":"crossref","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","article-title":"Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.","volume":"9","author":"A S\u00e1ez-Ciri\u00f3n","year":"2013","journal-title":"PLoS Pathog."},{"key":"pcbi.1008434.ref011","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nm.4108","article-title":"International AIDS Society global scientific strategy: towards an HIV cure 2016","volume":"22","author":"SG Deeks","year":"2016","journal-title":"Nat Med"},{"key":"pcbi.1008434.ref012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11904-016-0296-x","article-title":"Post-treatment controllers: Role in HIV \u201ccure\u201d research.","volume":"13","author":"LR Cockerham","year":"2016","journal-title":"Curr HIV\/AIDS Rep"},{"key":"pcbi.1008434.ref013","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI80561","article-title":"Towards HIV-1 remission: Potential roles for broadly neutralizing antibodies","volume":"126","author":"A Halper-Stromberg","year":"2016","journal-title":"J Clin Invest"},{"key":"pcbi.1008434.ref014","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/COH.0000000000000484","article-title":"Lessons learned from HIV antiretroviral treatment interruption trials","volume":"13","author":"Y Wen","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"pcbi.1008434.ref015","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"T Zhou","year":"2010","journal-title":"Science"},{"key":"pcbi.1008434.ref016","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"X Wu","year":"2010","journal-title":"Science"},{"key":"pcbi.1008434.ref017","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"KJ Bar","year":"2016","journal-title":"N Engl J Med"},{"key":"pcbi.1008434.ref018","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"M Caskey","year":"2015","journal-title":"Nature"},{"key":"pcbi.1008434.ref019","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: antibody effector functions in infectious diseases","volume":"18","author":"LL Lu","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"pcbi.1008434.ref020","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature21435","article-title":"Early antibody therapy can induce long-lasting immunity to SHIV","volume":"543","author":"Y Nishimura","year":"2017","journal-title":"Nature"},{"key":"pcbi.1008434.ref021","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"EN Borducchi","year":"2018","journal-title":"Nature"},{"key":"pcbi.1008434.ref022","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo","volume":"88","author":"RS Rudicell","year":"2014","journal-title":"J Virol"},{"key":"pcbi.1008434.ref023","first-page":"343","article-title":"The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption","volume":"30","author":"JZ Li","year":"2016","journal-title":"AIDS"},{"key":"pcbi.1008434.ref024","doi-asserted-by":"crossref","first-page":"e1002436","DOI":"10.1371\/journal.pmed.1002436","article-title":"Prospects for passive immunity to prevent HIV infection","volume":"14","author":"L Morris","year":"2017","journal-title":"PLoS Med"},{"key":"pcbi.1008434.ref025","doi-asserted-by":"crossref","first-page":"e1007626","DOI":"10.1371\/journal.pcbi.1007626","article-title":"Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials.","volume":"16","author":"DB Reeves","journal-title":"PLoS Comput Biol. 2020"},{"key":"pcbi.1008434.ref026","doi-asserted-by":"crossref","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.","volume":"7","author":"RM Lynch","year":"2015","journal-title":"Sci Transl Med."},{"key":"pcbi.1008434.ref027","doi-asserted-by":"crossref","first-page":"e1002435","DOI":"10.1371\/journal.pmed.1002435","article-title":"Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.","volume":"14","author":"KH Mayer","year":"2017","journal-title":"PLoS Med."},{"key":"pcbi.1008434.ref028","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1128\/JVI.03608-14","article-title":"HIV-1 Fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies","volume":"89","author":"RM Lynch","year":"2015","journal-title":"J Virol"},{"key":"pcbi.1008434.ref029","doi-asserted-by":"crossref","first-page":"e1007238","DOI":"10.1371\/journal.ppat.1007238","article-title":"Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies.","volume":"14","author":"Y Otsuka","year":"2018","journal-title":"PLoS Pathog"},{"key":"pcbi.1008434.ref030","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1089\/aid.2017.0063","article-title":"A 2-4-amino acid deletion in the V5 region of HIV-1 Env gp120 confers viral resistance to the broadly neutralizing human monoclonal antibody, VRC01","volume":"33","author":"S Tachibana","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"key":"pcbi.1008434.ref031","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/QAI.0000000000000595","article-title":"N463 glycosylation site on V5 loop of a mutant gp120 regulates the sensitivity of HIV-1 to neutralizing monoclonal antibodies VRC01\/03.","volume":"69","author":"W Wang","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pcbi.1008434.ref032","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coviro.2015.06.001","article-title":"HIV-1 genotypic drug resistance testing: digging deep, reaching wide?","volume":"14","author":"K Van Laethem","year":"2015","journal-title":"Curr Opin Virol"},{"key":"pcbi.1008434.ref033","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","article-title":"A quantitative approach for measuring the reservoir of latent HIV-1 proviruses","volume":"566","author":"KM Bruner","year":"2019","journal-title":"Nature"},{"key":"pcbi.1008434.ref034","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12981-018-0206-y","article-title":"Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay","volume":"15","author":"N Silver","year":"2018","journal-title":"AIDS Res Ther"},{"key":"pcbi.1008434.ref035","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm.4411","article-title":"Defining total-body AIDS-virus burden with implications for curative strategies","volume":"23","author":"JD Estes","year":"2017","journal-title":"Nat Med"},{"key":"pcbi.1008434.ref036","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1172\/JCI120194","article-title":"HIV-1 latent reservoir size and diversity are stable following brief treatment interruption","volume":"128","author":"DB Salantes","year":"2018","journal-title":"J Clin Invest"},{"key":"pcbi.1008434.ref037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pcbi.1002033","article-title":"A stochastic model of latently infected cell reactivation and viral blip generation in treated HIV patients","volume":"7","author":"JM Conway","year":"2011","journal-title":"PLoS Comput Biol"},{"key":"pcbi.1008434.ref038","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/COH.0000000000000490","article-title":"Modeling HIV persistence and cure studies","volume":"13","author":"AL Hill","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"pcbi.1008434.ref039","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1073\/pnas.1419162112","article-title":"Post-treatment control of HIV infection","volume":"112","author":"JM Conway","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pcbi.1008434.ref040","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.1250220","article-title":"Screening for noise in gene expression identifies drug synergies","volume":"344","author":"RD Dar","year":"2014","journal-title":"Science"},{"key":"pcbi.1008434.ref041","doi-asserted-by":"crossref","first-page":"13475","DOI":"10.1073\/pnas.1406663111","article-title":"Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1","volume":"111","author":"AL Hill","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pcbi.1008434.ref042","doi-asserted-by":"crossref","first-page":"e1000533","DOI":"10.1371\/journal.pcbi.1000533","article-title":"Modeling latently infected cell activation: Viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.","volume":"5","author":"L Rong","year":"2009","journal-title":"PLoS Comput Biol."},{"key":"pcbi.1008434.ref043","doi-asserted-by":"crossref","first-page":"e1007229","DOI":"10.1371\/journal.pcbi.1007229","article-title":"Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers.","volume":"15","author":"JM Conway","year":"2019","journal-title":"PLoS Comput Biol."},{"key":"pcbi.1008434.ref044","doi-asserted-by":"crossref","first-page":"e1005000","DOI":"10.1371\/journal.ppat.1005000","article-title":"HIV Reactivation from latency after treatment interruption occurs on average every 5\u20138 days\u2014Implications for HIV remission.","volume":"11","author":"M Pinkevych","year":"2015","journal-title":"PLoS Pathog."},{"key":"pcbi.1008434.ref045","doi-asserted-by":"crossref","first-page":"e1006004","DOI":"10.1371\/journal.pcbi.1006004","article-title":"Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.","volume":"14","author":"V Gupta","year":"2018","journal-title":"PLoS Comput Biol"},{"key":"pcbi.1008434.ref046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/msb.2010.4","article-title":"Intracellular transactivation of HIV can account for the decelerating decay of virus load during drug therapy","volume":"6","author":"CL Althaus","year":"2010","journal-title":"Mol Syst Biol"},{"key":"pcbi.1008434.ref047","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cell.2015.02.017","article-title":"An evolutionary role for HIV latency in enhancing viral transmission","volume":"160","author":"IM Rouzine","year":"2015","journal-title":"Cell"},{"key":"pcbi.1008434.ref048","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41577-018-0085-4","article-title":"Functional cure of HIV: the scale of the challenge","volume":"19","author":"MP Davenport","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"pcbi.1008434.ref049","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00002030-199805000-00006","article-title":"The frequency of resistant mutant virus before antiviral therapy","volume":"12","author":"RM Ribeiro","year":"1998","journal-title":"AIDS"},{"key":"pcbi.1008434.ref050","doi-asserted-by":"crossref","first-page":"7681","DOI":"10.1073\/pnas.97.14.7681","article-title":"Production of resistant HIV mutants during antiretroviral therapy","volume":"97","author":"RM Ribeiro","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pcbi.1008434.ref051","doi-asserted-by":"crossref","first-page":"e1000305","DOI":"10.1371\/journal.pcbi.1000305","article-title":"Timing the emergence of resistance to anti-HIV drugs with large genetic barriers.","volume":"5","author":"P Arora","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"pcbi.1008434.ref052","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.01010-10","article-title":"Estimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model","volume":"84","author":"S Gadhamsetty","year":"2010","journal-title":"J Virol"},{"key":"pcbi.1008434.ref053","doi-asserted-by":"crossref","first-page":"e1002527","DOI":"10.1371\/journal.pcbi.1002527","article-title":"Standing genetic variation and the evolution of drug resistance in HIV.","volume":"8","author":"PS Pennings","year":"2012","journal-title":"PLoS Comput Biol"},{"key":"pcbi.1008434.ref054","doi-asserted-by":"crossref","first-page":"e1002684","DOI":"10.1371\/journal.pcbi.1002684","article-title":"Stochastic simulations suggest that HIV-1 survives close to its error threshold.","volume":"8","author":"K Tripathi","year":"2012","journal-title":"PLoS Comput Biol"},{"key":"pcbi.1008434.ref055","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/nm.2892","article-title":"Antiretroviral dynamics determines HIV evolution and predicts therapy outcome","volume":"18","author":"DIS Rosenbloom","year":"2012","journal-title":"Nat Med"},{"key":"pcbi.1008434.ref056","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/ng.795","article-title":"A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase","volume":"43","author":"T Hinkley","year":"2011","journal-title":"Nat Genet"},{"key":"pcbi.1008434.ref057","doi-asserted-by":"crossref","first-page":"e1006313","DOI":"10.1371\/journal.ppat.1006313","article-title":"Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters","volume":"13","author":"OF Brandenberg","year":"2017","journal-title":"PLoS Pathog"},{"key":"pcbi.1008434.ref058","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/QAI.0000000000001101","article-title":"Viral decay dynamics and mathematical modeling of treatment response.","volume":"73","author":"A Shet","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pcbi.1008434.ref059","doi-asserted-by":"crossref","first-page":"11067","DOI":"10.1128\/JVI.74.23.11067-11072.2000","article-title":"Estimating relative fitness in viral competition experiments","volume":"74","author":"AFM Maree","year":"2000","journal-title":"J Virol"},{"key":"pcbi.1008434.ref060","doi-asserted-by":"crossref","first-page":"e1006114","DOI":"10.1371\/journal.ppat.1006114","article-title":"Experimental estimation of the effects of all amino-acid mutations to HIV\u2019s envelope protein on viral replication in cell culture","volume":"12","author":"HK Haddox","year":"2016","journal-title":"PLoS Pathog"},{"key":"pcbi.1008434.ref061","doi-asserted-by":"crossref","first-page":"e1008378","DOI":"10.1371\/journal.ppat.1008378","article-title":"HIV-1 variants are archived throughout infection and persist in the reservoir.","volume":"16","author":"K Brooks","year":"2020","journal-title":"PLoS Pathog."},{"key":"pcbi.1008434.ref062","doi-asserted-by":"crossref","first-page":"11514","DOI":"10.1073\/pnas.95.20.11514","article-title":"Drug concentration heterogeneity facilitates the evolution of drug resistance","volume":"95","author":"TB Kepler","year":"1998","journal-title":"Proc Natl Acad Sci"},{"key":"pcbi.1008434.ref063","doi-asserted-by":"crossref","first-page":"e1007222","DOI":"10.1371\/journal.ppat.1007222","article-title":"HIV control: Is getting there the same as staying there?","volume":"14","author":"P Goulder","year":"2018","journal-title":"PLoS Pathog"},{"key":"pcbi.1008434.ref064","doi-asserted-by":"crossref","first-page":"1243727","DOI":"10.1126\/science.1243727","article-title":"Virulence and Pathogenesis of HIV-1 Infection: An Evolutionary Perspective","volume":"343","author":"C Fraser","year":"2014","journal-title":"Science"},{"key":"pcbi.1008434.ref065","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cmpb.2013.04.014","article-title":"NIMROD: A program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations.","volume":"111","author":"M Prague","year":"2013","journal-title":"Comput Methods Programs Biomed."},{"key":"pcbi.1008434.ref066","doi-asserted-by":"crossref","DOI":"10.1201\/b17203","volume-title":"Mixed Effects Models for the Population Approach","author":"M. Lavielle","year":"2014"},{"key":"pcbi.1008434.ref067","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.tim.2014.08.006","article-title":"In vivo protection by broadly neutralizing HIV antibodies","volume":"22","author":"MJ van Gils","year":"2014","journal-title":"Trends Microbiol"},{"key":"pcbi.1008434.ref068","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/S2352-3018(19)30075-X","article-title":"Broadly neutralising antibodies in post-treatment control","volume":"6","author":"GJ de Bree","year":"2019","journal-title":"Lancet HIV"},{"key":"pcbi.1008434.ref069","doi-asserted-by":"crossref","first-page":"eaaz2686","DOI":"10.1126\/scitranslmed.aaz2686","article-title":"Multiple roles for HIV broadly neutralizing antibodies.","volume":"11","author":"BF Haynes","year":"2019","journal-title":"Sci Transl Med."},{"key":"pcbi.1008434.ref070","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2020.01.010","article-title":"Restriction of HIV-1 escape by a highly broad and potent neutralizing antibody","volume":"180","author":"P Schommers","year":"2020","journal-title":"Cell"},{"key":"pcbi.1008434.ref071","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"BF Keele","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"pcbi.1008434.ref072","doi-asserted-by":"crossref","first-page":"10489","DOI":"10.1128\/JVI.73.12.10489-10502.1999","article-title":"Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection","volume":"73","author":"R Shankarappa","year":"1999","journal-title":"J Virol"},{"key":"pcbi.1008434.ref073","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/S2352-3018(19)30053-0","article-title":"Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.","volume":"6","author":"TA Crowell","year":"2019","journal-title":"Lancet HIV"},{"key":"pcbi.1008434.ref074","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","article-title":"CD8 T cell exhaustion in chronic infection and cancer: Opportunities for interventions","volume":"69","author":"M Hashimoto","year":"2018","journal-title":"Annu Rev Med"},{"key":"pcbi.1008434.ref075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"LM McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"pcbi.1008434.ref076","article-title":"Vaccination alters the balance between protective immunity, exhaustion, escape, and death in chronic infections","author":"PLF Johnson","year":"2011","journal-title":"J Virol"},{"key":"pcbi.1008434.ref077","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/imcb.12161","article-title":"Modeling how reversal of immune exhaustion elicits cure of chronic hepatitis C after the end of treatment with direct-acting antiviral agents","volume":"96","author":"S Baral","year":"2018","journal-title":"Immunol Cell Biol"},{"key":"pcbi.1008434.ref078","doi-asserted-by":"crossref","first-page":"17393","DOI":"10.1073\/pnas.1902178116","article-title":"A dynamical motif comprising the interactions between antigens and CD8 T cells may underlie the outcomes of viral infections","volume":"116","author":"S Baral","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"pcbi.1008434.ref079","doi-asserted-by":"crossref","first-page":"e1446","DOI":"10.1002\/wsbm.1446","article-title":"Towards multiscale modeling of the CD8 + T cell response to viral infections","volume":"11","author":"S Baral","year":"2019","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"pcbi.1008434.ref080","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1126\/science.1207532","article-title":"Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing","volume":"333","author":"X Wu","year":"2011","journal-title":"Science"},{"key":"pcbi.1008434.ref081","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cell.2015.03.004","article-title":"Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection","volume":"161","author":"X Wu","year":"2015","journal-title":"Cell"},{"key":"pcbi.1008434.ref082","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"JF Scheid","year":"2011","journal-title":"Science"},{"key":"pcbi.1008434.ref083","article-title":"Basis and statistical design of the passive HIV-1 antibody mediated prevention (AMP) test-of-concept efficacy trials.","volume":"9","author":"PB Gilbert","year":"2017","journal-title":"Stat Commun Infect Dis."},{"key":"pcbi.1008434.ref084","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1080\/21645515.2018.1462640","article-title":"Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials.","volume":"14","author":"Y Huang","year":"2018","journal-title":"Hum Vaccines Immunother"},{"key":"pcbi.1008434.ref085","doi-asserted-by":"crossref","first-page":"e1007701","DOI":"10.1371\/journal.ppat.1007701","article-title":"Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs.","volume":"15","author":"R Raja","year":"2019","journal-title":"PLoS Pathog"},{"key":"pcbi.1008434.ref086","first-page":"1","article-title":"Viral rebound kinetics following single and combination immunotherapy for HIV \/ SIV.","author":"M Prague","year":"2019","journal-title":"bioRxiv"},{"key":"pcbi.1008434.ref087","doi-asserted-by":"crossref","first-page":"e1008064","DOI":"10.1371\/journal.pcbi.1008064","article-title":"Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection.","volume":"16","author":"R Desikan","year":"2020","journal-title":"PLoS Comput Biol"},{"key":"pcbi.1008434.ref088","doi-asserted-by":"crossref","first-page":"e1006478","DOI":"10.1371\/journal.ppat.1006478","article-title":"Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration","volume":"13","author":"EF Cardozo","year":"2017","journal-title":"PLoS Pathog"},{"key":"pcbi.1008434.ref089","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.aaf0972","article-title":"HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1","volume":"352","author":"T Schoofs","year":"2016","journal-title":"Science"},{"key":"pcbi.1008434.ref090","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1016\/j.celrep.2019.11.030","article-title":"Preferential presentation of high-affinity immune complexes in germinal centers can explain how passive immunization improves the humoral response","volume":"29","author":"AK Garg","year":"2019","journal-title":"Cell Rep"},{"key":"pcbi.1008434.ref091","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.cell.2015.04.016","article-title":"Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect","volume":"161","author":"DJ DiLillo","year":"2015","journal-title":"Cell"},{"key":"pcbi.1008434.ref092","article-title":"CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef","author":"BK Chen","year":"1996","journal-title":"J Virol"},{"key":"pcbi.1008434.ref093","doi-asserted-by":"crossref","first-page":"8198","DOI":"10.1073\/pnas.0407498102","article-title":"HIV dynamics with multiple infections of target cells","volume":"102","author":"NM Dixit","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"pcbi.1008434.ref094","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1107729108","article-title":"Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule","volume":"108","author":"L Josefsson","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"pcbi.1008434.ref095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.epidem.2015.09.001","article-title":"Influence of recombination on acquisition and reversion of immune escape and compensatory mutations in HIV-1.","volume":"14","author":"P Nagaraja","year":"2016","journal-title":"Epidemics"},{"key":"pcbi.1008434.ref096","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1371\/journal.pcbi.0030205","article-title":"Emergence of recombinant forms of HIV: Dynamics and scaling.","volume":"3","author":"GW Suryavanshi","year":"2007","journal-title":"PLoS Comput Biol"},{"key":"pcbi.1008434.ref097","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/S0140-6736(99)02035-8","article-title":"Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis","volume":"354","author":"B Ramratnam","year":"1999","journal-title":"Lancet"},{"key":"pcbi.1008434.ref098","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1021\/j100540a008","article-title":"Exact stochastic simulation of coupled chemical reactions","volume":"81","author":"DT Gillespie","year":"1977","journal-title":"J Phys Chem"},{"key":"pcbi.1008434.ref099","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jtbi.2003.09.002","article-title":"Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay","volume":"226","author":"NM Dixit","year":"2004","journal-title":"J Theor Biol"},{"key":"pcbi.1008434.ref100","doi-asserted-by":"crossref","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.","volume":"15","author":"MR Gaudinski","year":"2018","journal-title":"PLoS Med."}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1008434","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T15:19:03Z","timestamp":1607613543000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008434"}},"subtitle":[],"editor":[{"given":"Roger Dimitri","family":"Kouyos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":100,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1008434","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.02.14.940395","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]}}}